{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-145000","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.980419+00:00","generated_at":"2026-06-25T22:40:02.702281+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"AN2 Therapeutics appoints Maggie FitzPatrick as Class II director with option grant and cash retainer","bullets":["Appointed May 5, 2022; also joins nominating and corporate governance committee.","Initial stock option grant with grant-date value of $209,093 vesting monthly over 3 years.","Annual cash director retainer of $39,000 paid quarterly for board and committee service.","FitzPatrick brings experience from Johnson & Johnson, Cigna, and Exelon; also serves on VistaGen board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-145000","json":"https://secwatch.observer/filing/0001193125-22-145000.json","markdown":"https://secwatch.observer/filing/0001193125-22-145000.md","text":"https://secwatch.observer/filing/0001193125-22-145000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312522145000/0001193125-22-145000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312522145000/d286325d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:40:02.702281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"46810ca3c6","claim":"Margaret (Maggie) M. FitzPatrick was appointed as Class II Director at AN2 Therapeutics, Inc..","evidence_excerpt":"On May 5, 2022, Margaret (Maggie) M. FitzPatrick was appointed to the board of directors (the “ Board ”) of AN2 Therapeutics, Inc., a Delaware corporation (the “ Company ”), as a Class II Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312522145000/0001193125-22-145000-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}